Mantle Cell Lymphoma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

  • ID: 4449816
  • Report
  • Region: Global
  • 330 pages
  • VPA Research
1 of 3
Lymphoma is a cancer type where uncontrollable growth of lymphocytes (WBCs) initiating from lymph glands or lymphatic tissue or other parts of the lymphatic system, including bone marrow, tonsils, testicles, spleen and lymph nodes.

This excess growth of lymphocytes often accumulates in lymph nodes. Though this accumulation can occur in any body part, commonly affected parts are armpits, neck and groin and rarely in lungs or bones.

The non- inheritable and non- contageous disease is one of the common types of cancer but can be treated with patients’ life expectancy remaining quite large post- treatment.

Genomic alterations in lymphocytes cause damage to the lifecycle of these cells, boosting the cell division rate or affecting the death period. However, causes for such gene changes are yet to be determined.

Phases:
Phases of Lymphoma cancer
  • Single group of lymph nodes (above or below diaphragm)
  • Multiple group of lymph nodes are affected(above or below diaphragm)
  • Expands to both sides of diaphragm
  • Expands to bone marrow or other body parts
Types of Lymphoma Cancer

Though two types of Lymphoma are defined, it is often difficult to determine the exact sub- type of Lymphoma.

* Hodgkin Lymphoma
In Hodgkin Lymphoma, the cancer cells called Reed- Sternberg (RS) cells, have a characteristic appearance under microscope.
Further subtypes-

Nodular Sclerosis: Lymph nodes contain Reed- Sternberg cells mixed with normal white blood cells

Mixed Cellularity: Lymph nodes contain several Reed- Sternberg cells in addition to several other cell types

Lymphocyte- rich: Lymph nodes contain several normal- appearing lymphocytes and classic Reed- Sternberg cells

Lymphocyte- depleted: Lymph nodes contain large volume of Reed- Sternberg cells and few normal lymphocytes

Nodular lymphocyte- predominant Hodgkin lymphoma: Lymph nodes contain several abnormal B cells and Reed- Sternberg cells are rarely observed

* Non- Hodgkin Lymphoma
Unlike Hodgkin Lymphoma, the cancer cells called Reed- Sternberg cells are absent in this subtype of Lymphoma

High grade NHL

* B- cell NHL Lymphoma
Diffuse large B- cell (DLBCL): Abnormal growth of large B- Cells in different body parts

Intravascular B- Cell: Occurs due to explosion of lymphocytes within tiny vessels with no involvement of the organ parenchyma

Primary mediastinal large B- cell: Large neoplastic cells with B- cell derivation are observed

Burkitt: Most aggressive form, classified as endemic (African) type, sporadic type and HIV related

Primary central nervous system: DLBCL sub- type affecting the brain and or spinal cord

* T- cell NHL Lymphoma
Peripheral T- cell (PTCL NOS): Abnormal growth of T- cells which are not specified under any category

Anaplastic large cell: It can occur in the skin or in other organs throughout the body

Angioimmunoblastic T- cell: the body’s immune system does not recognize, and consequently destroys, its own cells and tissues

Enteropathy- associated: occurs in the intestines and is mostly associated with celiac disease

Nasal- type NK/T- cell: Natural killer cells often affecting the nasal area, trachea, gastrointestinal tract, or skin

Hepatosplenic T- cell: Abnormal growth of T- cells in liver or spleen

Lymphoblastic: The T- cells outgrow in number when a bone marrow cell develops alterations in its gene code

Low Grade NHL
Follicular: B- cells are affected; Enlargement of the lymph nodes in the neck, underarm, stomach, groin

Small lymphocytic: B- lymphocytes, with enlarged nodes affecting neck, armpit or groin

Lympho- plasmacytic: Enlarged cells make varying volumes of immunoglobin M protein in the blood, making it thick (condition referred to as Waldenstrom macroglobulinemi)

MALT Lymphoma (Gastric and Non- gastric): mucosa- associated lymphoid tissue (MALT) starts outside lymph nodes, usually in lymphatic tissue in the mucous membranes or tissues lining organs

Splenic marginal zone: The NHL sub- type affects spleen, bone marrow and blood

Nodal marginal zone: Mostly occurs in lymph nodes and rarely in spleen or bone marrow
Mantle Cell Lymphoma clinical trials report provides comprehensive analysis and trends in global Mantle Cell Lymphoma disease clinical trials. The research work analyzes the evolution of Mantle Cell Lymphoma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Mantle Cell Lymphoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Mantle Cell Lymphoma clinical trials.

Major drugs under development in Mantle Cell Lymphoma are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report
  • Number of Mantle Cell Lymphoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Mantle Cell Lymphoma
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Mantle Cell Lymphoma clinical trials worldwide are listed
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
High grade NHL
Low Grade NHL
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010- 2017
2.2.3 Prominent Companies in Global Mantle Cell Lymphoma Trials, 2010- 2017

3 Mantle Cell Lymphoma Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Mantle Cell Lymphoma
3.2 Mantle Cell Lymphoma Product Snapshots
3.2.1 Mantle Cell Lymphoma Drug Profiles

4 Global Mantle Cell Lymphoma Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010- 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010- 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010- 2017
4.4 Subjects Recruited by Region, 2010- 2017
4.5 Clinical Trials by Year, 2010- 2017
4.6 Subjects Recruited by Year, 2010- 2017
4.7 Clinical Trials by Development Phase, 2010- 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010- 2017
4.9 Clinical Trials by Status, 2010- 2017
4.10 Subjects Recruited by Trial Status, 2010- 2017
4.11 Clinical Trials by Sponsor Type, 2010- 2017
4.12 Subjects Recruited by Sponsor Type, 2010- 2017
4.13 Clinical Trials by Economy Type, 2010- 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010- 2017

5 Europe Mantle Cell Lymphoma Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010- 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010- 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010- 2017
5.4 Europe, Clinical Trials by Development Phase, 2010- 2017
5.5 Europe, Clinical Trials by Trial Status, 2010- 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010- 2017

6 Western Pacific Mantle Cell Lymphoma Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in Western Pacific, 2010- 2017
6.1.1 Western Pacific, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in Western Pacific, 2010- 2017
6.2.1 Western Pacific, Total Enrolment by Country
6.3 Western Pacific, Clinical Trials by Year, 2010- 2017
6.4 Western Pacific, Clinical Trials by Development Phase, 2010- 2017
6.5 Western Pacific, Clinical Trials by Trial Status, 2010- 2017
6.6 Western Pacific, Clinical Trials by Sponsor Type, 2010- 2017

7 South East Asia Mantle Cell Lymphoma Clinical Trial Research Trends

8 North America Mantle Cell Lymphoma Clinical Trial Research Trends
8.1 Clinical Trials by Top Countries in North America, 2010- 2017
8.1.1 North America, Clinical Trials by Country
8.2 Subjects Recruited by Top Countries in North America, 2010- 2017
8.2.1 North America, Total Enrolment by Country
8.3 North America, Clinical Trials by Year, 2010- 2017
8.4 North America, Clinical Trials by Development Phase, 2010- 2017
8.5 North America, Clinical Trials by Trial Status, 2010- 2017
8.6 North America, Clinical Trials by Sponsor Type, 2010- 2017

9 South and Central America Mantle Cell Lymphoma Clinical Trial Research Trends
9.1 Clinical Trials by Top Countries in South and Central America, 2010- 2017
9.1.1 South and Central America, Clinical Trials by Country
9.2 Subjects Recruited by Top Countries in South and Central America, 2010- 2017
9.2.1 South and Central America, Total Enrolment by Country
9.3 South and Central America, Clinical Trials by Year, 2010- 2017
9.4 South and Central America, Clinical Trials by Development Phase, 2010- 2017
9.5 South and Central America, Clinical Trials by Trial Status, 2010- 2017
9.6 South and Central America, Clinical Trials by Sponsor Type, 2010- 2017

10 Recent Clinical Trials- Snapshots
10.1 Mantle Cell Lymphoma Trial Snapshots- 2018
10.2 Mantle Cell Lymphoma Trial Snapshots- 2017
10.3 Mantle Cell Lymphoma Trial Snapshots- 2016
10.4 Mantle Cell Lymphoma Trial Snapshots- 2015
10.5 Mantle Cell Lymphoma Trial Snapshots- 2014
10.6 Mantle Cell Lymphoma Trial Snapshots- 2013
10.7 Mantle Cell Lymphoma Trial Snapshots- 2012
10.8 Mantle Cell Lymphoma Trial Snapshots- 2011
10.9 Mantle Cell Lymphoma Trial Snapshots- 2010

11 Appendix
11.1 About the Author
11.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Mantle Cell Lymphoma- Average Enrolment by Country, 2010- 2017
Figure 2: Mantle Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 3: Mantle Cell Lymphoma- Country wise Recruiting Sites, 2010- 2017
Figure 4: Mantle Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 5: Global Mantle Cell Lymphoma Clinical Trials Participation Share by Region, 2010- 2017
Figure 6: Global Mantle Cell Lymphoma Subjects Recruited by Region, 2010- 2017
Figure 7: Global Mantle Cell Lymphoma Clinical Trials by Year, 2010- 2017
Figure 8: Global Mantle Cell Lymphoma Subjects Recruited by Year, 2010- 2017
Figure 9: Global Mantle Cell Lymphoma Trials by Phase, 2010- 2017
Figure 10: Global Mantle Cell Lymphoma- Subjects Recruited by Phase, 2010- 2017
Figure 11: Global Mantle Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 12: Global Mantle Cell Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 13: Global Mantle Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 14: Global Mantle Cell Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 15: Global Mantle Cell Lymphoma- Clinical Trials by Type of Economy, 2010- 2017
Figure 16: Europe Mantle Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 17: Europe Mantle Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 18: Europe Mantle Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 19: Europe Mantle Cell Lymphoma Trials by Phase, 2010- 2017
Figure 20: Europe Mantle Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 21: Europe Mantle Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 22: Western Pacific Mantle Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 23: Western Pacific Mantle Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 24: Western Pacific Mantle Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 25: Western Pacific Mantle Cell Lymphoma Trials by Phase, 2010- 2017
Figure 26: Western Pacific Mantle Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 27: Western Pacific Mantle Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 28: North America Mantle Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 29: North America Mantle Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 30: North America Mantle Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 31: North America Mantle Cell Lymphoma Trials by Phase, 2010- 2017
Figure 32: North America Mantle Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 33: North America Mantle Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 34: South and Central America Mantle Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 35: South and Central America Mantle Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 36: South and Central America Mantle Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 37: South and Central America Mantle Cell Lymphoma Trials by Phase, 2010- 2017
Figure 38: South and Central America Mantle Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 39: South and Central America Mantle Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017

1.2 List of Tables
Table 1: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (2)
Table 3: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (3)
Table 4: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (4)
Table 5: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (5)
Table 6: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (6)
Table 7: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (7)
Table 8: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (8)
Table 9: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (9)
Table 10: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (10)
Table 11: Mantle Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (11)
Table 12: Mantle Cell Lymphoma- Region wise Clinical Trials, 2010- 2017
Table 13: Mantle Cell Lymphoma- Region wise Subjects Recruited, 2010- 2017
Table 14: Global Mantle Cell Lymphoma- Clinical Trials and Subjects by Trial Type, 2010- 2017
Table 15: Mantle Cell Lymphoma Trial Snapshots- 2018
Table 16: Mantle Cell Lymphoma Trial Snapshots- 2018
Table 17: Mantle Cell Lymphoma Trial Snapshots- 2018
Table 18: Mantle Cell Lymphoma Trial Snapshots- 2018
Table 19: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 20: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 21: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 22: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 23: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 24: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 25: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 26: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 27: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 28: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 29: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 30: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 31: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 32: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 33: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 34: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 35: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 36: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 37: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 38: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 39: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 40: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 41: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 42: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 43: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 44: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 45: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 46: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 47: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 48: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 49: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 50: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 51: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 52: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 53: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 54: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 55: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 56: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 57: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 58: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 59: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 60: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 61: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 62: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 63: Mantle Cell Lymphoma Trial Snapshots- 2017
Table 64: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 65: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 66: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 67: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 68: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 69: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 70: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 71: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 72: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 73: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 74: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 75: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 76: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 77: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 78: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 79: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 80: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 81: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 82: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 83: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 84: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 85: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 86: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 87: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 88: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 89: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 90: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 91: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 92: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 93: Mantle Cell Lymphoma Trial Snapshots- 2016
Table 94: Mantle Cell Lymphoma Trial Snapshots- 2015
Table 95: Mantle Cell Lymphoma Trial Snapshots- 2015
Table 96: Mantle Cell Lymphoma Trial Snapshots- 2015
Table 97: Mantle Cell Lymphoma Trial Snapshots- 2015
Table 98: Mantle Cell Lymphoma Trial Snapshots- 2015
Table 99: Mantle Cell Lymphoma Trial Snapshots- 2015
Table 100: Mantle Cell Lymphoma Trial Snapshots- 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll